Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Connecticut
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Connecticut
6 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in Connecticut.
Cities in Connecticut
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Site Number - 1621, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07032662A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Yale University School of Medicine- Site Number : 8400018, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06290141A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- New England Institute for Clinical Research, Stamford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06752356A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
- Cinical Study Site, New Haven
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT06858579A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Yale University School of Medicine, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jan 20, 2026 · NCT06747351A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
- Yale School Of Medicine, New Haven
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT06538064From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.